Aveo Pharmaceuticals Inc
NASDAQ:AVEO
Aveo Pharmaceuticals Inc
Revenue
Aveo Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aveo Pharmaceuticals Inc
NASDAQ:AVEO
|
Revenue
$94.3m
|
CAGR 3-Years
47%
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Aveo Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Aveo Pharmaceuticals Inc
Breakdown by Segments
Aveo Pharmaceuticals Inc
Total Revenue:
42.3m
USD
|
Gross Product Revenues:
45.7m
USD
|
Fotivda United States Product Revenue, Net:
38.9m
USD
|
Partnership Licensing And Royalty Revenue:
3.4m
USD
|
See Also
What is Aveo Pharmaceuticals Inc's Revenue?
Revenue
94.3m
USD
Based on the financial report for Sep 30, 2022, Aveo Pharmaceuticals Inc's Revenue amounts to 94.3m USD.
What is Aveo Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
65%
Over the last year, the Revenue growth was 269%. The average annual Revenue growth rates for Aveo Pharmaceuticals Inc have been 47% over the past three years , 65% over the past five years .